These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15279736)

  • 1. Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy.
    Hohlfeld R; Kappos L
    Int MS J; 2004 Sep; 11(2):61-3. PubMed ID: 15279736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prospects for neuroprotection in MS.
    Hohlfeld R
    Int MS J; 2003 Dec; 10(4):103-5. PubMed ID: 14977485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroprotection therapy of multiple sclerosis with high doses of ethylmethylhydroxypyridine succinate].
    Prakhova LN; Ilves AG; Savintceva ZI; Mineev KK; Nikiforova IG; Rubanik KS; Kataeva GV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):73-78. PubMed ID: 28139615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-mediated neurodegeneration and neuroprotection in MS.
    Giuliani F; Yong VW
    Int MS J; 2003 Dec; 10(4):122-30. PubMed ID: 14977489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia.
    Inglese M; Petracca M
    Schizophr Res; 2015 Jan; 161(1):94-101. PubMed ID: 24893901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
    Rottlaender A; Kuerten S
    Int J Mol Sci; 2015 Jul; 16(7):14850-65. PubMed ID: 26140377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurodegeneration and neuroprotection in multiple sclerosis].
    Davydovskaia MV; Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.
    Majlath Z; Annus A; Vecsei L
    Curr Drug Targets; 2018; 19(7):805-814. PubMed ID: 28017129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen.
    Christianson MS; Mensah VA; Shen W
    Maturitas; 2015 Feb; 80(2):133-9. PubMed ID: 25544310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodegeneration in multiple sclerosis: novel treatment strategies.
    Luessi F; Siffrin V; Zipp F
    Expert Rev Neurother; 2012 Sep; 12(9):1061-76; quiz 1077. PubMed ID: 23039386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancement of therapies for neuroprotection in multiple sclerosis.
    Lo A
    Expert Rev Neurother; 2008 Sep; 8(9):1355-66. PubMed ID: 18759548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
    Neuhaus O; Archelos JJ; Hartung HP
    Trends Pharmacol Sci; 2003 Mar; 24(3):131-8. PubMed ID: 12628358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T
    Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing therapeutic options in multiple sclerosis with neuroprotective properties.
    Stroet A; Linker RA; Gold R
    J Neural Transm (Vienna); 2013 Sep; 120 Suppl 1():S49-53. PubMed ID: 23720188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):123-8. PubMed ID: 23378992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibudilast for the treatment of multiple sclerosis.
    Goodman AD; Gyang T; Smith AD
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1231-7. PubMed ID: 27501293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple sclerosis at the time of world-wide use of disease modifying treatment].
    Gusev EI; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):4-9. PubMed ID: 19894306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection and neuroregeneration in multiple sclerosis.
    Stangel M
    J Neurol; 2008 Dec; 255 Suppl 6():77-81. PubMed ID: 19300964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.